Advertisement

Medical Oncology

, Volume 20, Issue 3, pp 291–294 | Cite as

Paclitaxel, carboplatin, and oral etoposide in advanced gastric adenocarcinoma

Association with severe myelotoxicity
  • Gil Bar-SelaEmail author
  • Diana Gaitini
  • Mariana Steiner
  • Nissim Haim
Original Article

Abstract

The prognosis of locally advanced or metastatic adenocarcinoma of the stomach is poor. In an attempt to improve therapeutic results, we undertook a phase II trial to investigate a combination of paclitaxel, carboplatin, and oral etoposide, all active drugs in this malignancy and with a synergistic effect in combination. Fourteen patients with advanced gastric adenocarcinoma were treated with paclitaxel 200 mg/m2 iv, carboplatin AUC-6 iv on d 1, and oral etoposide 50 mg/d alternating with 100 mg/d on d 1–10. Cycles were repeated every 3 wk. Of the 14 patients treated, partial response was observed in 3/12 (25%) evaluable patients. Median survival for the entire group was 7 mo. The treatment was associated with severe myelotoxicity. Neutropenic fever that required hospitalization developed in 7/14 (50%) of patients, and symptomatic anemia that required red blood cell transfusion was noted in 8/14 (57%). There was one drug-related death associated with neutropenic fever, Gram negative sepsis, grade 4 thrombocytopenia, and gastrointestinal bleeding. Nonhematological toxicity was moderate. We conclude that the current regimen of paclitaxel, carboplatin, and oral etoposide is not recommended in advanced gastric carcinoma owing to unacceptable myelotoxicity.

Key Words

Advanced gastric cancer carboplatin myelotoxicity oral etoposide paclitaxel 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive are alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71:587–591.PubMedGoogle Scholar
  2. 2.
    Glimelius B, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8:163–168.PubMedCrossRefGoogle Scholar
  3. 3.
    Vanhoefer U, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil and doxorubicin versus etoposide, leucovorin and fluorouracil versus infusion fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18:2648–2657.PubMedGoogle Scholar
  4. 4.
    Ajani JA, et al. Phase II study of taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 1998; 4:269–271.PubMedGoogle Scholar
  5. 5.
    Garcia AA, et al. Phase II trial of outpatient schedule of paclitaxel in patients with previously untreated metastatic, measurable adenocarcinoma of the stomach. Jpn J Clin Oncol 2001; 31:275–278.PubMedCrossRefGoogle Scholar
  6. 6.
    Kollmannsberger C, et al. A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 2000; 83:458–462.PubMedCrossRefGoogle Scholar
  7. 7.
    Philip PA, Zalupski MM, Gadgeel S, Hussain M, Shields A. A phase II study of carboplatin and paclitaxel in the treatment of patients with advanced esophageal and gastric cancer. Semin Oncol 1997; 24:86–88.Google Scholar
  8. 8.
    Ajani JA, Mansfield PF, Dumas P. Oral etoposide for patients with metastatic gastric adenocarcinoma. Cancer J Sci Am 1999; 5:112–114.PubMedGoogle Scholar
  9. 9.
    Hainsworth JD, Erland JB, Kalman LA, Schreeder MT, Greco FA. Carcinoma of unknown primary site: Treatment with 1-hour paclitaxel, carboplatin and extended-schedule etoposide. J Clin Oncol 1997; 15:2385–2393.PubMedGoogle Scholar
  10. 10.
    Common Toxicity Criteria. In: Investigator’s handbook: A manual for participants in clinical trails of investigational agents sponsored by the Division of Cancer Treatment, National Cancer Institute. NIH Pub 93-2770, 1993.Google Scholar
  11. 11.
    Bokemeyer C, et al. Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer. Semin Oncol 1997; 24:96–100.Google Scholar
  12. 12.
    Kornek GV, et al. Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erthropoietin in patients with advanced gastric cancer. Br J Cancer 2002; 86:1858–1863.PubMedCrossRefGoogle Scholar
  13. 13.
    Lokich JJ, et al. Combination paclitaxel, cisplatin and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas. Cancer 1999; 85:2347–2351.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc 2003

Authors and Affiliations

  • Gil Bar-Sela
    • 3
    Email author
  • Diana Gaitini
    • 1
  • Mariana Steiner
    • 2
  • Nissim Haim
    • 3
  1. 1.Department of Diagnostic Radiology, Rambam Medical Center and Faculty of MedicineTechnion-Israel Institute of TechnologyHaifaIsrael
  2. 2.Department of OncologyLin Medical CenterHaifaIsrael
  3. 3.Department of OncologyRambam Medical CenterHaifaIsrael

Personalised recommendations